But it looks unlikely that Lilly will be able to maintain this with the launch of Humalog, which is available in vial form or as a disposable pen. Sanofi fights back This represents Sanofi's first ...

That means companies such as Lilly, Novo Nordisk, Sanofi and AstraZeneca will soon ... management system combines a connected insulin pen with glucose-sensing technologies (e.g., glucose meter ...

They’re followed by Lilly, Johnson & Johnson, Novo, AstraZeneca, Novartis, Pfizer and finally Sanofi in the projected rankings. In terms of drug sales buoying those company rankings, Lilly’s ...

In this photo is a Zepbound injection pen ... Novo Nordisk's Wegovy (semaglutide),” GlobalData said in a report the market research firm released Tuesday. “Recently, Eli Lilly announced ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema ...

In 2023, the global disposable pen injectors market is expected to be worth USD 25.5 billion. The market is expected to reach USD 54.4 billion by 2033, expanding at a 7.9% CAGR throughout the forecast ...

SHANGHAI, Dec 20 (Reuters) - As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some ...

Enter Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the makers behind blockbuster glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro, Zepbound, Ozempic, and Wegovy -- all of which are ...